DGAP-News: HepaRegeniX initiates a preclinical collaboration with the Netherlands Cancer Institute to explore the potential of its 2nd MKK4 inhibitor HRX-0233 for use in cancer combination ther
Retrieved on:
Wednesday, October 20, 2021
Netherlands Cancer Institute, Biology, Dutch Cancer Society, MAP2K4, MAP, All European Academies, Colorectal cancer, Diagnosis, KRAS, Translational research, News, MEK, Valorisation, MKK4, DGAP, Cancer research, Research, Cancer Science, Liver regeneration, Quality of life, Justicia oncodes, Hepatocyte, Patient, Economy, Novo Holdings A/S, Cancer, Pharmaceutical industry, HepaRegeniX GmbH -, the Oncode Institute, Utrecht, HEPAREGENIX GMBH -, THE ONCODE INSTITUTE, UTRECHT
MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.
Key Points:
- MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.
- This new and unique therapeutic concept was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany.
- Investors in HepaRegeniX include the Boehringer Ingelheim Venture Fund (BIVF), Novo Holdings A/S, Coparion, High-Tech Gruenderfonds and Ascenion GmbH.
- About the Netherlands Cancer Institute, Amsterdam - www.nki.nl
The Netherlands Cancer Institute , founded in 1913, is among the world's best comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care.